Inaperisone is a pyrrolidinopropiophenone derivative patented by Japanese pharmaceutical company Hokuriku Pharmaceutical Co. as muscle-relaxant and antispasmodic agent.

Naftoxate is an antimicotic agent. It is effective against both gram-positive and gram-negative bacteria as well as yeasts and other fungi in plant cell culture.

Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Brequinar had been in phase II clinical trials by Bristol-Myers Squibb for the treatment of cancer and transplant rejection. However, this research has been discontinued. Brequinar had been also in preclinical studys for the treatment of cytomegalovirus infections. However, this research has been discontinued.

Dopamantine is the adamantine derivative. It combined elements of both amantadine and dopamine in its structure, shares some pharmacological effects of amantadine. Dopamantine is the anti-Parkinson drug, which has passed clinical trials. Dopamantine showed a high activity against Plasmodium berghei parasites that cause malaria.

Mepiprazole is a psychotropic pyrazole derivative. Mepiprazole is a serotonin reuptake inhibitor and adrenolytic. In clinical studies, it demonstrated anxiolytic properties.

Carocainide is a benzofuran derivative patented by pharmaceutical company Delalande S. A. For treatment cardiovascular disease. Carocainide showing antiarrhythmic properties in animal models. In isolated papillary muscles and Purkinje fibers it decreases the maximum rate of rise of the action potential and in Purkinje fibers it decreases the plateau amplitude and the duration of the action potential. Carocainide increases the ratio of the effective refractory period to the action potential duration at 90% of repolarization, shifts the membrane responsiveness curve towards more negative membrane potentials and slows down the recovery of the maximum rate of rise of the action potentials of the Purkinje fibers. Carocainide also increases the conduction time at the Purkinje papillary muscle junction.

Cetefloxacin is an oral fluoroquinolone derivative with potent antibacterial activity against a broad spectrum of microorganisms being particularly active against gram-positive bacteria. Cetefloxacin is highly toxic and mortality was recorded among rats receiving 2000 or 1000 mg/kg/d. Rats receiving dosages of 450 or 2000/1000 mg/kg/d showed less activated mandibular lymph nodes, cortical lymphocyte depletion of mandibular and/or mesenteric lymph nodes, atrophy of the white pulp of the spleen, cortical atrophy of thymus and thymic apoptosis. Enlarged caeca, increased water consumption and variations in plasma electrolyte levels were observed in animals receiving these dosages and in male rats receiving 100 mg/kg/d. Low neutrophil counts were observed in rats receiving dosages of 100 or 450 mg/kg/d, and increased alkaline phosphatase and alanine transaminase plasma levels and slightly decreased plasma protein levels in females receiving 450 or 2000/1000 mg/kg/d. Marmosets receiving dosages of 50 mg/kg/d and above displayed several clinical signs which included emesis, diarrhoea, ptosis, occasional episodes of under- and overactivity, and excessive scratching activity. Skin reddening was observed during the first week of treatment in marmosets receiving 300 mg/kg/d.

FEPROSIDNINE, also known as Sidnofen, is a psychostimulant and monoamine oxidase inhibitor developed in USSR.

Dersalazine is a locally-acting compound. It is a potent platelet activating factor (PAF)-antagonist. Dersalazine inhibited IL-1beta or TNF-alpha production in THP-1 or U937 cells, respectively. Dersalazine sodium reduced colonic proinflammatory cytokines IL-1b, IL-6, and IL-17 in dextran sodium sulphate (DSS)–induced colitis. After oral administration, dersalazine sodium is mostly unabsorbed until it reaches the large bowel where the azo bond is reduced by bacteria releasing the active compound. Dersalazine had been in phase I clinical trial for the treatment of ulcerative colitis. No serious adverse reactions were detected in clinical trial. However, no recent development has been reported.

Bromerguride is an ergot derivative with dopamine antagonistic activity. Bromerguride has been claimed to bind to 5-HT1A receptors and to have 5-HT agonist properties. The neuropharmacological effects caused by the drug in animals were characterized by a central depressant neuroleptic-like symptomatology; the neuroleptic activity of the Bromerguride being at least in the same order of magnitude as haloperidol.